Compare Quest Diagnostics Inc (DGX) vs InMode Ltd (INMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs InMode Ltd — how do they compare? Quest Diagnostics Inc trades at $206.04 (market cap $22.80B), while InMode Ltd trades at $15.24 (market cap $857.04M). The key difference: Quest Diagnostics Inc is far larger — about 26.6× InMode Ltd's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while InMode Ltd pays none. Which is the better fit depends on your goals.
| DGX | INMD | |
|---|---|---|
Market Cap | $22.80B | $857.04M |
Sector | Health | Technology |
52-Week High | $216.02 | $16.62 |
52-Week Low | $166.42 | $12.76 |
Enterprise Value | $28.82B | $324.71M |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
INMD trades at $15.15, down 0.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company maintains strong profitability with a 77.84% gross margin and a P/E of 11.04, indicating potential undervaluation. Recent news includes an unsolicited acquisition offer at $16.75 per share and upcoming Q2 2026 earnings on August 5, 2026, with revenue guidance of $95.2M-$95.4M.
The outlook is mixed: solid fundamentals and a takeover bid provide upside potential, but risks include earnings misses, legal investigations, and shareholder opposition to the acquisition. Analyst consensus is a $16.50 price target with a balanced buy/hold split, suggesting cautious optimism amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →
